196 related articles for article (PubMed ID: 37996322)
21. NVX-CoV2373-induced T- and B-cellular immunity in immunosuppressed people with multiple sclerosis that failed to respond to mRNA and viral vector SARS-CoV-2 vaccines.
Mueller-Enz M; Woopen C; Katoul Al Rahbani G; Haase R; Dunsche M; Ziemssen T; Akgün K
Front Immunol; 2023; 14():1081933. PubMed ID: 37545513
[TBL] [Abstract][Full Text] [Related]
22. NVX-CoV2373-induced cellular and humoral immunity towards parental SARS-CoV-2 and VOCs compared to BNT162b2 and mRNA-1273-regimens.
Hielscher F; Schmidt T; Klemis V; Wilhelm A; Marx S; Abu-Omar A; Ziegler L; Guckelmus C; Urschel R; Sester U; Widera M; Sester M
J Clin Virol; 2022 Dec; 157():105321. PubMed ID: 36279695
[TBL] [Abstract][Full Text] [Related]
23. Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents: A Randomized Clinical Trial.
Áñez G; Dunkle LM; Gay CL; Kotloff KL; Adelglass JM; Essink B; Campbell JD; Cloney-Clark S; Zhu M; Plested JS; Roychoudhury P; Greninger AL; Patel N; McGarry A; Woo W; Cho I; Glenn GM; Dubovsky F;
JAMA Netw Open; 2023 Apr; 6(4):e239135. PubMed ID: 37099299
[TBL] [Abstract][Full Text] [Related]
24. Immunogenicity and safety of third-dose mRNA COVID-19 vaccines in healthy adults previously vaccinated with two doses of the ChAdOx1 vaccine.
Sheng WH; Ieong SM; Lin PH; Hsieh MJ; Yang HC; Pan CF; Chao TL; Chang SY; Chang SC
J Formos Med Assoc; 2023 Feb; 122(2):121-131. PubMed ID: 36127206
[TBL] [Abstract][Full Text] [Related]
25. Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial.
Bennett C; Rivers EJ; Woo W; Bloch M; Cheung K; Griffin P; Mohan R; Deshmukh S; Arya M; Cumming O; Neville AM; Pardey TM; Plested JS; Cloney-Clark S; Zhu M; Kalkeri R; Patel N; Buchanan A; Marcheschi A; Swan J; Smith G; Cho I; Glenn GM; Walker R; Mallory RM
J Infect Dis; 2023 Nov; ():. PubMed ID: 37970668
[TBL] [Abstract][Full Text] [Related]
26. Safety of the NVX-CoV2373 COVID-19 vaccine in randomized placebo-controlled clinical trials.
Smith K; Hegazy K; Cai MR; McKnight I; Rousculp MD; Alves K
Vaccine; 2023 Jun; 41(26):3930-3936. PubMed ID: 37211453
[TBL] [Abstract][Full Text] [Related]
27. Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial.
Heath PT; Galiza EP; Baxter DN; Boffito M; Browne D; Burns F; Chadwick DR; Clark R; Cosgrove CA; Galloway J; Goodman AL; Heer A; Higham A; Iyengar S; Jeanes C; Kalra PA; Kyriakidou C; Bradley JM; Munthali C; Minassian AM; McGill F; Moore P; Munsoor I; Nicholls H; Osanlou O; Packham J; Pretswell CH; San Francisco Ramos A; Saralaya D; Sheridan RP; Smith R; Soiza RL; Swift PA; Thomson EC; Turner J; Viljoen ME; Fries L; Cho I; McKnight I; Glenn G; Rivers EJ; Robertson A; Alves K; Smith K; Toback S
Clin Infect Dis; 2023 Feb; 76(3):398-407. PubMed ID: 36210481
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant.
Shinde V; Bhikha S; Hoosain Z; Archary M; Bhorat Q; Fairlie L; Lalloo U; Masilela MSL; Moodley D; Hanley S; Fouche L; Louw C; Tameris M; Singh N; Goga A; Dheda K; Grobbelaar C; Kruger G; Carrim-Ganey N; Baillie V; de Oliveira T; Lombard Koen A; Lombaard JJ; Mngqibisa R; Bhorat AE; Benadé G; Lalloo N; Pitsi A; Vollgraaff PL; Luabeya A; Esmail A; Petrick FG; Oommen-Jose A; Foulkes S; Ahmed K; Thombrayil A; Fries L; Cloney-Clark S; Zhu M; Bennett C; Albert G; Faust E; Plested JS; Robertson A; Neal S; Cho I; Glenn GM; Dubovsky F; Madhi SA;
N Engl J Med; 2021 May; 384(20):1899-1909. PubMed ID: 33951374
[TBL] [Abstract][Full Text] [Related]
29. Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
Taucher C; Lazarus R; Dellago H; Maurer G; Weisova P; Corbic-Ramljak I; Dubischar K; Lilja A; Eder-Lingelbach S; Hochreiter R; Jaramillo JC; Junker H; Krammer M; Pusic P; Querton B; Larcher-Senn J; Hoffmann M; Pöhlmann S; Finn A;
J Infect; 2023 Sep; 87(3):242-254. PubMed ID: 37406777
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in nonhuman primates.
Routhu NK; Stampfer SD; Lai L; Akhtar A; Tong X; Yuan D; Chicz TM; McNamara RP; Jakkala K; Davis-Gardner ME; St Pierre EL; Smith B; Green KM; Golden N; Picou B; Jean SM; Wood J; Cohen J; Moore IN; Patel N; Guebre-Xabier M; Smith G; Glenn G; Kozlowski PA; Alter G; Ahmed R; Suthar MS; Amara RR
Sci Immunol; 2023 Oct; 8(88):eadg7015. PubMed ID: 37191508
[TBL] [Abstract][Full Text] [Related]
31. Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.
Shaw RH; Greenland M; Stuart ASV; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Darton T; Dinesh T; Duncan CJA; Faust SN; Ferreira DM; Finn A; Goodman AL; Green CA; Hallis B; Heath PT; Hill H; Lambe T; Libri V; Lillie PJ; Morey E; Mujadidi YF; Payne R; Plested EL; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Screaton GR; Singh N; Turner DPJ; Turner PJ; White R; Nguyen-Van-Tam JS; Liu X; Snape MD;
J Infect; 2023 Jun; 86(6):574-583. PubMed ID: 37028454
[TBL] [Abstract][Full Text] [Related]
32. Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages.
Bhiman JN; Richardson SI; Lambson BE; Kgagudi P; Mzindle N; Kaldine H; Crowther C; Gray G; Bekker LG; ; Shinde V; Bennett C; Glenn GM; Madhi SA; Moore PL
Sci Rep; 2023 Jan; 13(1):1222. PubMed ID: 36681693
[TBL] [Abstract][Full Text] [Related]
33. Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial.
Wu JD; Li JX; Liu J; Wang HM; Zhou GH; Li J; Wu D; Chen X; Feng Y; Qi XY; Wang X; Gou JB; Ma TL; Yang XY; Xu LF; Wan P; Zhu T; Wang ZF; Zhu FC;
Lancet Infect Dis; 2023 Sep; 23(9):1020-1030. PubMed ID: 37216958
[TBL] [Abstract][Full Text] [Related]
34. Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial.
Lee IT; Cosgrove CA; Moore P; Bethune C; Nally R; Bula M; Kalra PA; Clark R; Dargan PI; Boffito M; Sheridan R; Moran E; Darton TC; Burns F; Saralaya D; Duncan CJA; Lillie PJ; San Francisco Ramos A; Galiza EP; Heath PT; Girard B; Parker C; Rust D; Mehta S; de Windt E; Sutherland A; Tomassini JE; Dutko FJ; Chalkias S; Deng W; Chen X; Feng J; Tracy L; Zhou H; Miller JM; Das R;
Lancet Infect Dis; 2023 Sep; 23(9):1007-1019. PubMed ID: 37348519
[TBL] [Abstract][Full Text] [Related]
35. Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants.
Lyke KE; Atmar RL; Dominguez Islas C; Posavad CM; Deming ME; Branche AR; Johnston C; El Sahly HM; Edupuganti S; Mulligan MJ; Jackson LA; Rupp RE; Rostad CA; Coler RN; Bäcker M; Kottkamp AC; Babu TM; Dobrzynski D; Martin JM; Brady RC; Frenck RW; Rajakumar K; Kotloff K; Rouphael N; Szydlo D; PaulChoudhury R; Archer JI; Crandon S; Ingersoll B; Eaton A; Brown ER; McElrath MJ; Neuzil KM; Stephens DS; Post DJ; Lin BC; Serebryannyy L; Beigel JH; Montefiori DC; Roberts PC;
NPJ Vaccines; 2023 Jul; 8(1):98. PubMed ID: 37433788
[TBL] [Abstract][Full Text] [Related]
36. Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine.
Heath PT; Galiza EP; Baxter DN; Boffito M; Browne D; Burns F; Chadwick DR; Clark R; Cosgrove C; Galloway J; Goodman AL; Heer A; Higham A; Iyengar S; Jamal A; Jeanes C; Kalra PA; Kyriakidou C; McAuley DF; Meyrick A; Minassian AM; Minton J; Moore P; Munsoor I; Nicholls H; Osanlou O; Packham J; Pretswell CH; San Francisco Ramos A; Saralaya D; Sheridan RP; Smith R; Soiza RL; Swift PA; Thomson EC; Turner J; Viljoen ME; Albert G; Cho I; Dubovsky F; Glenn G; Rivers J; Robertson A; Smith K; Toback S;
N Engl J Med; 2021 Sep; 385(13):1172-1183. PubMed ID: 34192426
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico.
Dunkle LM; Kotloff KL; Gay CL; Áñez G; Adelglass JM; Barrat Hernández AQ; Harper WL; Duncanson DM; McArthur MA; Florescu DF; McClelland RS; Garcia-Fragoso V; Riesenberg RA; Musante DB; Fried DL; Safirstein BE; McKenzie M; Jeanfreau RJ; Kingsley JK; Henderson JA; Lane DC; Ruíz-Palacios GM; Corey L; Neuzil KM; Coombs RW; Greninger AL; Hutter J; Ake JA; Smith K; Woo W; Cho I; Glenn GM; Dubovsky F;
N Engl J Med; 2022 Feb; 386(6):531-543. PubMed ID: 34910859
[TBL] [Abstract][Full Text] [Related]
38. Estimated Effectiveness of a Primary Cycle of Protein Recombinant Vaccine NVX-CoV2373 Against COVID-19.
Mateo-Urdiales A; Sacco C; Petrone D; Bella A; Riccardo F; Del Manso M; Bressi M; Siddu A; Brusaferro S; Palamara AT; Rezza G; Pezzotti P; Fabiani M;
JAMA Netw Open; 2023 Oct; 6(10):e2336854. PubMed ID: 37792377
[TBL] [Abstract][Full Text] [Related]
39. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice.
Tian JH; Patel N; Haupt R; Zhou H; Weston S; Hammond H; Logue J; Portnoff AD; Norton J; Guebre-Xabier M; Zhou B; Jacobson K; Maciejewski S; Khatoon R; Wisniewska M; Moffitt W; Kluepfel-Stahl S; Ekechukwu B; Papin J; Boddapati S; Jason Wong C; Piedra PA; Frieman MB; Massare MJ; Fries L; Bengtsson KL; Stertman L; Ellingsworth L; Glenn G; Smith G
Nat Commun; 2021 Jan; 12(1):372. PubMed ID: 33446655
[TBL] [Abstract][Full Text] [Related]
40. NVX-CoV2373 induces humoral and cellular immune responses that are functionally comparable to vector and mRNA-based vaccines.
Mai F; Kordt M; Bergmann-Ewert W; Reisinger EC; Müller-Hilke B
Front Immunol; 2024; 15():1359475. PubMed ID: 38562927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
